Paul Matteis
Stock Analyst at Stifel
(0.50)
# 3,258
Out of 4,829 analysts
111
Total ratings
28.57%
Success rate
-25.79%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $270.19 | +27.69% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.69 | +188.81% | 2 | Mar 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reinstates: Buy | $78 | $58.97 | +32.28% | 1 | Mar 5, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $12.90 | +148.06% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $10.16 | +214.96% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $3.91 | +181.33% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $439.37 | +12.43% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $13.15 | +143.35% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $6.75 | -11.11% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.20 | +233.33% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.34 | +327.35% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $17.70 | +238.98% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $31.27 | +15.13% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $61.37 | +41.76% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $12.56 | +425.48% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $10.47 | +234.29% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $33.53 | +58.07% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $17.52 | +19.86% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $3.83 | +657.18% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $120.43 | +19.57% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $124.40 | +130.71% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.63 | +660.46% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.32 | +417.24% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.51 | +1,489.40% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.27 | +1,751.85% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $12.18 | +162.73% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.53 | +848.62% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.05 | +2,471.43% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.59 | +45.99% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.60 | +869.70% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $19.43 | +1,649.87% | 1 | Dec 21, 2016 |
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $270.19
Upside: +27.69%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.69
Upside: +188.81%
Rhythm Pharmaceuticals
Mar 5, 2025
Reinstates: Buy
Price Target: $78
Current: $58.97
Upside: +32.28%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $12.90
Upside: +148.06%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $10.16
Upside: +214.96%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $3.91
Upside: +181.33%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $439.37
Upside: +12.43%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $13.15
Upside: +143.35%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $6.75
Upside: -11.11%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.20
Upside: +233.33%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.34
Upside: +327.35%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $17.70
Upside: +238.98%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $31.27
Upside: +15.13%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $61.37
Upside: +41.76%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $12.56
Upside: +425.48%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $10.47
Upside: +234.29%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $33.53
Upside: +58.07%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $17.52
Upside: +19.86%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $3.83
Upside: +657.18%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $120.43
Upside: +19.57%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $124.40
Upside: +130.71%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $2.63
Upside: +660.46%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.32
Upside: +417.24%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.51
Upside: +1,489.40%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.27
Upside: +1,751.85%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $12.18
Upside: +162.73%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $2.53
Upside: +848.62%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.05
Upside: +2,471.43%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $9.59
Upside: +45.99%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.60
Upside: +869.70%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $19.43
Upside: +1,649.87%